The Biggest Scandals In Girl Scout Cookie History
Of course, we can't forget about the Girl Scouts' iconic cookies. From fans expressing excitement over new cookie releases to hoping that a discontinued favorite will return, the nonprofit has captivated cookie lovers nationwide for over 100 years. What started as a high school fundraising effort evolved into a cultural phenomenon, with Girl Scout cookies becoming a household name and a key part of the institution's identity.
Beyond its famous cookies, Girl Scouts has built a strong reputation for fostering entrepreneurship in young girls. Its marketing strategies (including limited-edition cookie flavors and popular snack collaborations with companies like Yoplait and General Mills) have kept the organization relevant in an ever-changing market. Despite Girl Scouts' legacy of empowerment and success, the group and its famous cookies have seen their share of controversy, including cases of alleged embezzlement and more recent concerns over potential toxins.
Read more: The 7 Lowest And 6 Highest Quality Ice Cream Brands To Look Out For
For years, Girl Scouts has claimed its cookies contain no trans fats, but past labeling practices may have been misleading. Under FDA guidelines, foods with less than 0.5 grams of trans fat per serving could be labeled as having zero grams of trans fats, even if they contained partially hydrogenated oils. This allowed food manufacturers, including Girl Scouts, to manipulate serving sizes to meet labeling requirements. This means cookies like Thin Mints, Tagalongs, and Samoas once contained small amounts of trans fats while being labeled as trans fat-free.
This concern, however, is outdated. In 2015, the FDA began phasing trans fats out of the U.S. food supply after determining that they were broadly unsafe. Manufacturers nationwide were required to comply fully by January 1, 2020, meaning that Girl Scout cookies no longer contain hydrogenated oils today. While the organization has always followed legal guidelines, given its reputation for integrity, Girl Scouts might have benefited from greater transparency about the cookies' contents. The cookies, of course, still contain natural trans fats like butter and milk, but these are not affected by the FDA ban.
Girl Scouts has faced repeated criticism for using palm oil in the nonprofit's cookies, an ingredient linked to deforestation and child labor. Despite years of advocacy from members within the institution — including two Girl Scouts who launched a petition in 2011 after learning about palm oil's environmental impact — Girl Scout cookies still contain palm oil. Investigations have found that the palm oil supply chain often involves unsustainable practices that contribute to rainforest destruction, endangering species like orangutans. Additionally, a 2020 report uncovered child and forced labor in the palm oil industry, raising ethical concerns about the sourcing of this ingredient.
This controversy is particularly damaging because it contradicts Girl Scouts' values of ethical decision making, responsibility, and supporting local communities. However, the nonprofit has taken steps toward more sustainable routes. Girl Scouts has pledged to source "sustainable" palm oil through the Roundtable on Sustainable Palm Oil (RSPO), though critics argue that this certification does not fully prevent environmental harm or labor exploitation.
One reason why Girl Scouts relies so heavily on palm oil is because the organization needed a replacement for hydrogenated oils and trans fats after the FDA determined them to be unsafe. Given Girl Scouts' emphasis on empowering young girls and fostering social responsibility, the organization's unwillingness to fully address these concerns has led to growing frustration among members and activists.
In 2018, Patricia Cascione, a former Girl Scouts troop treasurer in Santa Clarita, California, was charged with embezzling more than $58,000 from Girl Scouts of the USA's troops and a Girl Scouts service unit. Cascione volunteered as a treasurer for various LA County Girl Scout troops over the course of 20 years. In 2019, she was found guilty of embezzling over $93,000 over a four-year period from GSUSA and the Beverly Hills Cancer Center. The case concluded with Cascione pleading no contest to the charges, resulting in a sentencing of one year of jail time, followed by five years of probation — in addition to an order to repay the stolen funds.
This incident is among several in which Girl Scout leaders have been accused of misappropriating funds. In 2023, a Girl Scout troop treasurer from Delaware was arrested for allegedly stealing over $12,000 from her former troop. Similarly, a former Girl Scout troop leader in Oklahoma was accused of embezzling more than $5,000 from her troop back in 2010. The funds taken were earned from cookie sales and donations intended to honor a Girl Scout leader who had died. Though the motivations varied, these repeated incidents display the need for more financial checks and balances within Girl Scout troops.
Money isn't the only asset being stolen from the Girl Scouts. In 2017, Leah Ann Vick, a 26-year-old Girl Scout troop leader from Kentucky, was indicted for allegedly stealing over $26,000 worth of Girl Scout cookies. Over the course of a few months, Vick reportedly collected more than 6,000 boxes. However, when the time came to disperse the cookies to troops and collect the proceeds, Vick was unresponsive, leading to failed attempts by the organization to recover the funds.
It was unclear whether Vick had kept the cookies, sold them herself and kept the cash, distributed some to troops and pocketed the proceeds, or a combination of all three. This prompted the nonprofit to involve law enforcement, resulting in her indictment on felony theft charges. The outcome of the legal proceedings remains uncertain from available reports. Girl Scout cookie sales are essential to the financial health of a troop, as the profits allow the young girls to fund educational trips and events.
In March 2025, Girl Scouts of the USA faced a class-action lawsuit alleging that its cookies contain harmful substances, including heavy metals and pesticides. This lawsuit, filed by New York resident Amy Mayo, asks for $5 million in damages and for future cookie packaging to clearly disclose the discovered substances. The lawsuit references a 2024 study conducted by Moms Across America and GMO Science, which tested several varieties of cookies. The study reportedly found traces of heavy metals such as arsenic, lead, and mercury in all samples. The study also found glyphosate, a type of pesticide, in 13 cookies.
Girl Scouts responded by affirming that the organization's cookies are safe and comply with all food safety regulations. The organization noted that trace amounts of heavy metals and glyphosate can occur naturally and are commonly found in many varieties of food products. Food safety experts, however, have questioned the study's validity, citing its small sample size and lack of peer review. Time will tell the results of the lawsuit, but rest assured, the cookies still follow FDA guidelines.
Read the original article on Mashed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff
WASHINGTON (AP) — The government's top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval of two COVID-19 vaccines, disregarding recommendations from government scientists, according to federal documents released Wednesday. The new memos from the Food and Drug Administration show how the agency's vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots from vaccine makers Novavax and Moderna. Both vaccines were approved by the FDA in May after months of analysis by rank-and-file FDA reviewers. But internal correspondence show Prasad disagreed with staffers who planned to approve the shots for everyone 12 and older, similar to previous COVID vaccines. The scientists had concluded the benefit from the vaccines and the risk of COVID-19 outweighed the risk of possible side effects, which are rare. Instead Prasad decided the shots should be limited to those who face special risks from the virus— seniors or children and adults with underlying medical issues. Prasad explained that the COVID vaccine benefits must be reconsidered in light of falling rates of death and hospitalization and the possibility for vaccine side effects. It's the latest in a series of vaccine restrictions imposed by officials working under Kennedy, who has long questioned the benefits of vaccines. 'Even rare vaccination related harms both known and unknown now have higher chance of outweighing potential benefits' Prasad wrote in a five-page memo explaining his decision. COVID-19 remains a public health threat, resulting in 32,000 to 51,000 U.S. deaths and more than 250,000 hospitalizations since last fall, according to the Centers for Disease Control and Prevention. Most at risk for hospitalization are seniors and children under 2 — especially infants under 6 months. Top FDA leaders are typically not involved in the review of individual products. Officials like Prasad can overrule staffers, but such cases are rare and often controversial. News of the FDA documents was first reported by the New York Times. Prasad was hired to lead the FDA's vaccine center in May, after the previous director, Dr. Peter Marks, was forced to resign over disagreements with Kennedy. An academic researcher specializing in cancer therapies, Prasad came to prominence during the pandemic for criticizing public health measures, including the FDA's approval of COVID boosters for healthy adults and children. Since arriving at the agency he has worked with FDA Commissioner Mark Makary on new guidelines that will limit approvals of future COVID boosters to higher-risk Americans, mainly seniors and those with medical conditions like asthma and obesity. Those limits match the terms FDA recently approved for Novavax's shot, Nuvaxovid and Moderna's mNexspike. Novavax's vaccine is the only protein-based coronavirus vaccine available in the U.S. Moderna's vaccine is an updated, lower-dose version of its existing mRNA-based vaccine. The review team for the Novavax vaccine pointed to data from a study in 30,000 adults, concluding that 'the risk-benefit assessment for this vaccine technology remains favorable.' FDA staff reached a similar conclusion for the Moderna vaccine, deeming it similar in safety and effectiveness to the company's original shot. Last week, the FDA finalized new warning labeling about the risk of myocarditis, a rare form of heart inflammation, on shots from Moderna and Pfizer, the other maker of an mRNA-based shot for COVID. In his 'override memo,' reversing FDA staff's decision on the Moderna shot, Prasad pointed to the ongoing risk of myocarditis and questions about its frequency. The agency ordered Moderna to conduct further studies of the risk as a condition for the approving its updated shot. A spokesman for the administration said Prasad 'has raised serious concerns' about the issue. 'We will not ignore these risks and will ensure that the gold standard of science is used for any decisions,' said Andrew Nixon, in an emailed statement. Outside researchers have noted that cases of the heart condition tend to resolve quickly and are less severe than those associated with COVID infection itself, which can also cause myocarditis. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Associated Press
4 hours ago
- Associated Press
UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.
LONDON, UK / ACCESS Newswire / July 3, 2025 / UTILITY therapeutics Ltd. (UTILITY), a biotechnology company focused on the development of PIVYA (pivmecillinam 185 mg tablets), a penicillin class antibacterial approved by the U.S. Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infection (uUTI), today announced that it has been acquired by Alembic Pharmaceuticals, Inc. (Alembic). PIVYA marked the first antibiotic in approximately 20 years to earn FDA approval for uUTI, a common bacterial infection that afflicts millions of women annually. The FDA approved PIVYA in April 2024 for use in female patients 18 years of age and older with uUTI caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. PIVYA has a unique mechanism of action that targets the cell wall of gram-negative bacteria. Additional U.S. prescribing information about PIVYA can be found at 'We are thrilled that Alembic Pharmaceuticals understands the clinical and commercial value of PIVYA and will bring this proven treatment to female patients in need across the U.S.,' said Tom Hadley, President and CEO of UTILITY therapeutics. 'With current therapies failing and the armament of uUTI antibiotics perilously thin, PIVYA provides U.S. clinicians with a new and effective treatment option that has a long safety record. We are grateful for the support of our Board of Directors and investors, including the AMR Action Fund, whose collective support was instrumental in helping us obtain FDA approval for PIVYA.' The UTILITY therapeutics Ltd. Board of Directors and Observers includes: 'The acquisition of UTILITY and the commercialization of PIVYA are important steps in Alembic's strategic goal to provide branded pharmaceutical products to the U.S. healthcare market,' said Craig Salmon, President of Alembic Pharmaceuticals, Inc. 'PIVYA will further enhance Alembic's ability to build long-term value by combining global research, regulatory, and manufacturing strengths with a sharpened focus on specialty segments. Alembic plans to make PIVYA available in the U.S. in the 4th quarter of 2025.' 'I am excited to see Alembic drive the commercialization of PIVYA, which is uniquely positioned to help millions of American women with urinary tract infections,' said Dr. Morten Sommer, Professor of microbiology at the Technical University of Denmark, and co-founder and board member of UTILITY therapeutics. 'With a novel mechanism of action, not previously deployed in the U.S., PIVYA can become a cornerstone of the treatment of urinary tract infections based on its first-line positioning in the Infectious Disease Society of America treatment guidelines. On behalf of the co-founders, investors, and Board of Directors, we are excited that PIVYA will help address the societal impact of the uUTI disease burden in women.' About PIVYA (pivmecillinam oral tablets 185mg) PIVYA, an oral prodrug of mecillinam, is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. Mecillinam demonstrated in vitro activity against Enterobacterales in the presence of some beta-lactamases and extended-spectrum beta-lactamases (ESBL) of the following groups: CTX-M, SHV, TEM, AmpC. The inhibitory action of mecillinam on PBP-2 results in low cross-resistance with certain beta-lactams. The frequency of resistance to mecillinam in E. coli range from 8×10-8 to 2×10-5 when exposed to 32-256 times MIC. PIVYA has been proven safe and effective in three clinical trials with the most common Adverse Reactions Occurring in ≥1% of Patients Receiving PIVYA (Adjusted for Study Size); Nausea (4.3%), Diarrhea (2.1%), Vulvovaginal candidiasis (1.8%), Genital pruritus (1.8%), and Headache (1.4%). PIVYA demonstrated strong response in three controlled clinical trials comparing different PIVYA dosing regimens to placebo (Trial 1), to another oral antibacterial drug (Trial 2), or to ibuprofen (Trial 4) evaluated the efficacy of pivmecillinam for the treatment of uUTI. Efficacy was assessed in the Microbiological Intent-to-Treat (micro-ITT) population which included all randomized subjects with a positive baseline urine culture defined as ≥105 colony-forming-units (CFU)/mL of a uropathogen where CFU count was available and no more than 2 species of microorganisms, regardless of colony count, and no baseline pathogen was non-susceptible to the active comparator. The composite response rates (composite endpoint of clinical cure and microbiological response), as well as clinical cure and microbiological response rates of the recommended 185 mg three times daily dosing regimen. Composite Response Rates (Clinical Cure and Microbiological Response) at TOC in the uUTI trials (Micro ITT Population) Clinical Cure Rates (Micro-ITT Population) Microbiological Response Rates (Micro-ITT Population) Contraindications Warnings and precautions About UTILITY therapeutics Ltd. UTILITY has exclusive U.S. commercial rights to two European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections (UTI). Pivmecillinam is an oral prodrug of mecillinam that has been approved by the FDA for the treatment of women with uncomplicated urinary tract infections. PIVYA has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases. Mecillinam, an intravenous (IV) formulation, may be developed as a first-line therapy for complicated UTI (cUTI) in the hospital setting. For more information, contact David Cobb, Alembic Pharmaceuticals [email protected] 908-552-583 SOURCE: Utility Therapeutics Ltd. press release
USA Today
5 hours ago
- USA Today
How to keep your pets calm during Fourth of July fireworks
Get out the grill and prepare to celebrate Independence Day with BBQs, lawn chairs, and delicious food! The Fourth of July is perfect for gathering with friends, family, and pets. Just remember, while fireworks are fun for many, they can be frightening for some animals. Loud noises like fireworks or thunderstorms are the cause of nearly one in five lost pets, a survey from the American Society for the Prevention of Cruelty to Animals found. While we celebrate our Independence Day, here's how to keep your four-legged friends safe and happy: Petting your dog If possible, your dog should stay home with at least one human so it can be reassured if it gets anxious. Stay with your pet in a room that has minimal windows and play soft music or a movie to distract from fireworks and other noises. A little affection goes a long way – one of the best ways to calm your dog down is to give it strong, firm pats to let it know you're there, says veterinarian Diana Watkins, who owns 143 Veterinary Services in Massachusetts. Thundershirt You can try anxiety-reducing devices like a Thundershirt, which acts like a weighted blanket to soothe your dog. Medication For extra-nervous dogs, there are situational anxiety medications your vet can prescribe. They can be helpful during loud sensory events like thunderstorms and fireworks or when you're leaving your dog alone for longer than normal. Watkins advises giving your dog only veterinary-grade products because over-the-counter anti-anxiety and CBD supplements are often not FDA-regulated and can be harmful to your pup. Collar with ID Make sure your pet has an ID tag on at all times, or invest in a GPS locator for its collar if your pet isn't microchipped. Take a walk before nighttime It's a good idea to time walks earlier in the day before the fireworks start. Keep your dog on lead if you think fireworks will be set off. Consider Hiring a Trainer If fireworks and fear is impacting your animal, you can consider hiring a trainer. Working with a trainer of behavior consultant to desensitize your dog to fireworks gradually. It's never to late to plan for the next fireworks event. Sources: USA TODAY Network reporting and research; American Kennel Club
